Inventor · Stanford, CA, US

Andrew J. Perlman

16Patents
7h-index
3Co-inventors
51Inventor score

Filing activity: Jun 24, 2013 → Mar 2, 2020

Most-cited inventions

PatentTitleAreaCited byStatus
US9198898B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 20 Active
US8906951B1 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 16 Active
US9381188B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 11 Active
US9737507B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 7 Active
US9486439B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 7 Active
US9737508B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 7 Active
US9474741B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 7 Active
US9974769B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 5 Active
US9968588B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 5 Active
US10278952B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 3 Active
US10278953B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 3 Active
US10617671B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 1 Active
US10702499B2 Use of NK-1 receptor antagonists in pruritus Emerging Cross-Sectional Technologies 1 Active
US9707208B2 Use of NK-1 receptor antagonist serlopitant in pruritus General 0 Revoked
US11026920B2 Use of NK-1 receptor antagonist serlopitant in pruritus Emerging Cross-Sectional Technologies 0 Active
US9707209B2 Use of NK-1 receptor antagonists in pruritus General 0 Revoked

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.